article thumbnail

Number of ongoing US drug shortages reaches new high, pharmacist group says

Fierce Pharma

as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001. . | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S.

Biopharma 315
article thumbnail

Lilly looks inward as it completes hunt for new CFO with appointment of 23-year vet Lucas Montarce

Fierce Pharma

Montarce, who’s been with the Indianapolis-based drugmaker since 2001, most recently worked as Lilly's president and general manager for the company’s hub in Spain, Portugal and Greece.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Regulatory-first for gene editing therapy

European Pharmaceutical Review

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.

article thumbnail

Intellia’s gene editing therapy shows early potential in rare heart condition

Pharmaceutical Technology

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.

52
article thumbnail

W. Va. judge sides with drug distributors in bellwether opioid trial

MedCity News

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Biopharma 100
article thumbnail

Officials Release Draft Legislation Aimed at Prescription Drug Shortage Issues

Pharmacy Times

Ongoing and active shortages are currently at the highest number since January 2001.

article thumbnail

FDA grants orphan drug status for Ichnos’ multiple myeloma antibody

Pharmaceutical Technology

The US FDA has granted orphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.

FDA 52